Search the Newsreel

Aemetis (AMTX) Stock Pops As Operating Profit Returns But Cash Risk Lingers

Aemetis (AMTX) stock saw a 5.5% pop after its Q2 earnings release, driven by a return to operating profit of $5.8m and a 20% revenue increase to $62.7m, despite an ongoing net loss of $9.4m. The company's positive performance is attributed to low carbon …

Haemonetics Corporation (HAE) Stock forecasts

Argus has raised its target price for Haemonetics Corporation (HAE) stock to $90.00. The company, currently trading at $86.61, focuses on improving patient care and reducing healthcare costs through its medical products and solutions for blood and plasma collection, surgical suites, and hospital transfusion …

Aemetis Inc (AMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aemetis Inc (AMTX) has an earnings forecast score of 7.50, ranking 11th in the Renewable Energy industry, with an average price target of $3.00. Analysts largely recommend a "Buy" for AMTX, with the next quarter's revenue expected at $78.46 million and EPS at -$0.24.

Agnico Eagle Mines (AEM) Is Up 23.1% After Record Free Cash Flow And Lower Production Guidance

Is Haemonetics (HAE) Undervalued As Q1 Earnings And Outlook Lift Optimism?

Braemar Hotels & Resorts: Ashford Is Gone, But Problems Remain (NYSE:BHR)

Haemonetics Q1 Earnings Call Highlights

Key Points Interested in Haemonetics Corporation? Here are five stocks we like better. Haemonetics raised its fiscal 2027 outlook, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, after first-quarter revenue increased 6% to $339 million and adjusted EPS rose 4% …

Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen has upgraded Haemonetics (NYSE:HAE) to a "strong-buy" rating, reflecting positive analyst sentiment and strong financial performance. The company exceeded quarterly expectations with $1.14 EPS and $339.38 million in revenue, leading management to raise its fiscal 2027 revenue-growth outlook to 5%-8%. Haemonetics' …

Haemonetics (HAE) Stock Extends Run As Cash Flow Strength Meets Margin Pressure

ETFs Investing in Agnico Eagle Mines Limited Stocks

This article from TradingView lists various ETFs that include Agnico Eagle Mines Limited (AE9) stock in their holdings. The ETFs are sorted by market value and provide details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and …

Agnico Eagle Mines Climbs as Investors Respond to Record Quarterly Free Cash Flow and Resilient Guidance

Agnico Eagle Mines (AEM) saw its stock rise after reporting record quarterly free cash flow and maintaining its production guidance. This positive financial performance and outlook have resonated well with investors, indicating confidence in the company's operational efficiency and future prospects.

Agnico Eagle Mines Ltd Stock (AEM) Moved Up by 6.22% on Aug 7: What Investors Need To Know

Agnico Eagle Mines Ltd (AEM) stock surged by 6.22% on August 7th, driven by a rally in spot gold prices and expectations of a more dovish stance from the Federal Reserve. The company reaffirmed its production targets and maintained healthy operating margins, with analysts …

Agnico-Eagle Mines Ltd. stock rises Friday, outperforms market

Agnico-Eagle Mines Ltd. (AEM) saw its stock rise by 5.94% to C$249.37 on Friday, outperforming the broader Canadian market. The S&P/TSX Composite Index (GSPTSE) also rose by 0.68% to 36,381.23. Despite this gain, Agnico-Eagle Mines Ltd.'s closing price was 28.5% below its 52-week high …

HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $95 FROM $89

Barrington Research has increased its target price for Haemonetics Corp (HAE.N) to $95 from $89. This adjustment reflects an updated valuation for the company. The article cites Reuters as the source of this information.

Earnings call transcript: Haemonetics beats Q1 2026 estimates, stock slips premarket

Haemonetics (HAE) reported stronger-than-expected fiscal first-quarter results, with adjusted EPS of $1.14 on revenue of $339 million, exceeding analyst estimates. Despite the beat and raised full-year revenue guidance, the stock declined 1.91% in premarket trading, indicating investor focus on the company's cautious outlook and …

Agnico Eagle Mines (AEM) Earnings Jump Following Buyback But Is The Valuation Case Priced In

Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Haemonetics Corp (HAE), detailing its current price momentum score of 4.19 and its trading range between a resistance level of $91.33 and a support level of $75.97. It evaluates various technical indicators, including MACD, RSI, and moving …

Agnico Eagle Mines (AEM) Q2 2026 Earnings Call Transcript

HAEMONETICS CORP 2026: Revenue $339.38M, EPS $0.72— 10-Q Summary

HAEMONETICS CORP reported strong financial results for the 2026 quarter, with revenue increasing by 5.6% year-over-year to $339.38 million. Diluted EPS also saw a rise to $0.72. The company attributed its revenue growth to expanded Apheresis plasma volume and market share gains in its …

Aemetis reports 20% revenue growth for Q2

Aemetis reported a 20% revenue growth for the second quarter. This article highlights the company's financial performance and is part of a series of reports on the ethanol industry's Q2 results, including Green Plains and Alto.

Aemetis Q2 2026 Earnings Call Transcript

Aemetis reported strong Q2 2026 results with a 20% year-over-year revenue increase to $62.7 million and a significant improvement in adjusted EBITDA to $9.7 million, driven by higher ethanol and RNG volumes, improved pricing, and Section 45Z credits. The company is advancing key capital …

Haemonetics (NYSE: HAE) grows revenue 5.6% in Q1 2027

Haemonetics Corporation (NYSE: HAE) reported a 5.6% increase in net revenues for Q1 fiscal 2027, reaching $339.38 million. Operating income grew by 6.7% to $57.46 million, while diluted EPS rose 2.9% to $0.72. The company also detailed its segment reorganization into Apheresis and MedSurg, …

Form 8K Aemetis Inc For: 6 August By Investing.com

This article reports that Aemetis Inc. filed a Form 8K on August 6th, 2026. Aemetis Inc. (AMTX) stock performance is noted as +5.52%. The article reiterates the filing information and provides stock market data for various indices, commodities, and shares.

Haemonetics Corporation 2027 Q1 - Results - Earnings Call Presentation (NYSE:HAE) 2026-08-06

Earnings call transcript: Aemetis posts smaller loss in Q2 2026 as revenue misses

Aemetis reported strong Q2 2026 results with a 20% year-over-year revenue increase to $62.7 million and a significant improvement in adjusted EBITDA to $9.7 million, driven by higher ethanol and RNG volumes, improved pricing, and Section 45Z credits. The company is advancing key capital …

BTIG raises Haemonetics stock price target to $96 on strong results

BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $96 from $84, maintaining a Buy rating after the company reported strong first-quarter revenues and adjusted earnings per share that surpassed consensus estimates. All segments performed well, with Interventional Technologies returning to growth …

Aemetis, Inc. (AMTX) Stock Price, News, Quote & History

Aemetis, Inc. (AMTX) stock closed at $1.63, up 5.16%, with pre-market activity showing further gains. The renewable natural gas and fuels company, headquartered in Cupertino, California, specializes in low and negative carbon intensity products. Analysts have an average price target of $13.88 for AMTX, …

Aemetis (AMTX) Reports Q2 Loss, Misses Revenue Estimates

Aemetis Inc earnings beat by $0.13, revenue fell short of estimates

Aemetis Inc (NASDAQ: AMTX) reported second-quarter earnings per share (EPS) of $-0.130, surpassing analyst estimates by $0.13. However, the company's revenue of $62.7 million fell short of the consensus estimate of $69.89 million. The stock has seen a significant decline over the past 3 …

Aemetis Q2 2026 earnings: Tax credits restore operating profit

Aemetis (NASDAQ: AMTX) reported Q2 2026 revenue of $62.7 million, a 20% increase year-over-year, with diluted loss per share narrowing to $0.13. The company's operating income turned positive at $5.8 million, primarily due to Section 45Z tax credits, lower corn costs, and higher Dairy …

Press Release: Aemetis Reports Second Quarter 2026 Financial Results

The article is a press release announcing Aemetis's financial results for the second quarter of 2026. It will detail the company's performance during this period, likely including revenue, expenses, and other key financial metrics.

Opawica Explorations set to Unlock the Arrowhead Property: Permitted 10,000-Metre Drill Strategy Targets High-Grade Gold System Adjacent to Agnico Eagle's Laronde Complex

Nearly a Century of Exploration, Historical High-Grade Gold, Modern Drilling, Advanced 3D Modelling and 25 High-Priority Targets Position Arrowhead for Its Next Major Phase of Exploration VANCOUVER, BC - August 6, 2026 (NEWMEDIAWIRE) - Opawica Explorations Inc. (TSXV: OPW) (FSE: A2PEAD) (OTCQB: OPWEF) (the …

Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates

Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 5.6% year on year to $339.4 million. Its non-GAAP profit of $1.14 per share was 5.8% above analysts' consensus …

Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

Haemonetics Corporation announced that its first quarter fiscal year 2027 financial results, for the period ending June 27, 2026, are now available on its Investor Relations website. The company will also host a conference call and webcast on August 6, 2026, at 8:00 a.m. …

Haemonetics sets Aug. 6 webcast to discuss fiscal Q1 results

Haemonetics (NYSE: HAE) announced that its financial results for the first quarter of fiscal 2027, which ended June 27, 2026, are now available on its Investor Relations website. The company will host an investor conference call and live webcast on August 6, 2026, at …